PHO raises product growth guidance to 10–12% as diagnostics expansion speeds up
PHO lifted its full-year product growth guidance to 10–12%, after third-quarter product revenue rose 7% at constant currency, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, product revenue in the third quarter rose 7% at constant currency. The company raised its full-year product growth guidance to 10–12%.
The adjusted EBITDA margin held at 14%. The Vesica acquisition widens the diagnostic portfolio, while the third-quarter net loss reflected higher financial costs.
why it matters
Investors will focus on two signals: faster sales and growth in diagnostics driven by the deal. Higher financial costs weigh on net profit, so the final result depends on how those costs develop.
market impact
PHO shares: raised growth guidance supports interest in the stock, while higher financial costs weigh on profit
- PHO shares pressure up — raised revenue growth guidance supports investor expectations
tags
instruments
sources
- PHO: Product growth guidance rose to 10–12% as diagnostic expansion accelerated — TradingView, 28 October 2026 at 07:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗